Trial · NCT00700999
Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)
NCT00700999, Phase 4, Completed, US Department of Veterans Affairs; results first posted 2014-06-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD). Trials, record NCT00700999. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00700999
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)
- NCT number
- NCT00700999
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 65 participants, actual
- Lead sponsor
- US Department of Veterans Affairs
- Conditions
- Post-traumatic Stress Disorder
- Interventions
- Paroxetine
- First posted
- 2008-06-19
- Last updated
- 2014-06-03
- Results first posted
- 2014-06-03
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) | Baseline and 12 weeks | Mean percent change in brain response in the prefrontal cortex during an emotion reappraisal task in the treatment (paroxetine) group and in the Combat Exposed Control group. Target areas are analyzed from fMRI scans which were completed before participants receive treatment and again after participants received 12 weeks of treatment with paroxetine (20-40mg QD). Combat Exposed Control participants received an fMRI scan after signing initial consent and again 12 weeks later. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) | Baseline and 12 weeks | The number of participants analyzed is only 17 in each arm. The total number of participants in the Intervention group who completed fMRI scans pre-treatment and post treatment is only 19, in the Combat Exposed Control Group it is 18. Three of the participants scans were removed from data analysis due to the level of movement during the scan. | percent change in BOLD signal | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) | Treatment (Paroxetine) Group | -.92 | Standard Deviation 0.90 | percent change in BOLD signal | |
| Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) | Combat Exposed Control | .07 | Standard Deviation 1.78 | percent change in BOLD signal |
Source ClinicalTrials.gov
Participant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Paroxetine) Group | 36 | |
| Overall Study | STARTED | Combat Exposed Controls | 29 | |
| Overall Study | First MRI Scan | Treatment (Paroxetine) Group | 29 | |
| Overall Study | First MRI Scan | Combat Exposed Controls | 22 | |
| Overall Study | Second MRI Scan | Treatment (Paroxetine) Group | 19 | |
| Overall Study | Second MRI Scan | Combat Exposed Controls | 18 | |
| Overall Study | COMPLETED | Treatment (Paroxetine) Group | 21 | |
| Overall Study | COMPLETED | Combat Exposed Controls | 20 | |
| Overall Study | NOT COMPLETED | Treatment (Paroxetine) Group | 15 | |
| Overall Study | NOT COMPLETED | Combat Exposed Controls | 9 |
Source ClinicalTrials.gov
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Psychological/Emotional Adverse Event | Psychiatric disorders | Treatment (Paroxetine) Group | 5 | 28 | 5 |
| other | Psychological/Emotional Adverse Event | Psychiatric disorders | Combat Exposed Controls | 0 | 29 | 0 |
| other | Anxiety experience during fMRI scanning | Psychiatric disorders | Treatment (Paroxetine) Group | 2 | 29 | 2 |
| other | Anxiety experience during fMRI scanning | Psychiatric disorders | Combat Exposed Controls | 1 | 22 | 1 |
| other | Physical Side Effect to Medication - Blurred Vision | Psychiatric disorders | Treatment (Paroxetine) Group | 8 | 36 | 8 |
| other | Physical Side Effect to Medication - Blurred Vision | Psychiatric disorders | Combat Exposed Controls | 0 | 0 | 0 |
| other | Physical Side Effect to Medication - Chest Pain | Psychiatric disorders | Treatment (Paroxetine) Group | 7 | 36 | 7 |
| other | Physical Side Effect to Medication - Chest Pain | Psychiatric disorders | Combat Exposed Controls | 0 | 0 | 0 |
| other | Physical Side Effect to Medication - Constipation | Psychiatric disorders | Treatment (Paroxetine) Group | 8 | 36 | 8 |
| other | Physical Side Effect to Medication - Constipation | Psychiatric disorders | Combat Exposed Controls | 0 | 0 | 0 |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Paroxetine) Group | ||
| Total, all-cause mortality | Combat Exposed Controls | ||
| Total, other adverse events | Treatment (Paroxetine) Group | 28 | 36 |
| Total, other adverse events | Combat Exposed Controls | 1 | 29 |
| Total, serious adverse events | Treatment (Paroxetine) Group | 0 | 36 |
| Total, serious adverse events | Combat Exposed Controls | 0 | 29 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Treatment (Paroxetine) Group vs Combat Exposed Controls: serious adverse events |
Source Trial comparisons
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Emotion Regulation Task | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00700999
GET https://conductscience.org/api/trials/v1/NCT00700999/events?page=2